Cedars-Sinai Cancer appoints director of melanoma research
Click Here to Manage Email Alerts
Bin Zheng, PhD, has been appointed director of melanoma research in the department of biomedical sciences at Cedars-Sinai Cancer.
Zheng is recognized for his expertise in immunotherapy and targeted therapies.
His research focuses on the metabolism of melanoma cancer cells and the tumor microenvironment, as well as how to overcome resistance to targeted therapies.
“Melanoma is a difficult cancer to treat, and collaborating with my peers to improve survival through better treatments is my goal,” Zheng said in a press release. “We’ve made a lot of progress in targeted immunotherapies over the last decade. There are still many challenges, but we’ve made important scientific discoveries that could translate into new therapies for [patients with] melanoma.”
Zheng previously served as assistant professor of dermatology, pathology and cell biology at the Institute for Cancer Genetics at Columbia University, as well as associate professor of dermatology at Harvard Medical School.
“Dr. Zheng’s expertise in melanoma research and focus on translating his findings into personalized and targeted immunotherapies will strengthen our knowledge around prevention, diagnosis and treatment of melanoma, the deadliest form of skin cancer,” Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer, said in the release. “We are thrilled to have Dr. Zheng on our team and look forward to continued progress for patients with melanoma.”
Read more about
Click Here to Manage Email Alerts